News and Events

Aug. 31, 2018 - Western Oncolytics CSO Steve Thorne To Chair Roundtable Discussion at Upcoming Oncolytic Virotherapy Summit 2018 in Boston

Steve Thorne to lead workshop on selecting & optimizing therapeutic transgenes for oncolytic viruses

Aug. 28, 2017 - Western Oncolytics CSO Steve Thorne to Present at Cambridge Healthtech Institute's 5th Annual Immuno-Oncology Summit

Steve Thorne describes latest developments from lead program, WO-12

Dec. 6, 2016 - NPR Interviews Western Oncolytics Founder Steve Thorne

Local Pittsburgh NPR station WESA features interview with Steve Thorne

Sept. 8, 2016 - Western Oncolytics Featured in Pittsburgh Post-Gazette Following Pfizer Deal

Pittsburgh Post-Gazette showcases local biotech startup Western Oncolytics and recent investment by Pfizer

July 28, 2016 - Western Oncolytics and Pfizer Announce Immuno-Oncology Research Collaboration for Lead Program, WO-12

Companies plan to advance Western Oncolytics' lead preclinical therapy into human testing

June 22, 2015 - Western Oncolytics Closes $2.5M Series A to Advance Cancer Immunotherapy

Funds will advance novel oncolytic immunotherapy towards clinical use

June 18, 2014 - Western Oncolytics Receives $275,000 Seed Funding for Development of Cancer Immunotherapy

Unique immuno-oncolytic therapy gets closer to a more effective, safer cancer treatment